Successful treatment of acute heart failure in COVID-19-induced cytokine storm with tocilizumab : a case report
© The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology..
BACKGROUND: SARS-CoV-2 is known to induce a cytokine storm, a hyperinflammatory state driven by up-regulation of interleukin 6 (IL-6) and immunomodulatory chemokines that may result in acute heart failure.
CASE SUMMARY: A 65-year-old woman with confirmed SARS-CoV-2 developed shock with multiorgan system failure, including acute biventricular heart failure, 2 weeks after the initial onset of fever, cough, and shortness of breath. The patient experienced myocardial recovery within 48 h after administration of tocilizumab, a humanized monoclonal anti-IL-6 receptor antibody, and multiple supportive vasoactive medications.
DISCUSSION: The differential diagnosis of acute heart failure in critically ill patients with COVID-19 infection is broad, including sepsis-induced cardiomyopathy, Takotsubo syndrome, viral lymphocytic myocarditis, and acute coronary syndrome. Immunomodulatory treatment with tocilizumab may benefit patients who develop cardiogenic shock associated with SARS-CoV-2-induced cytokine storm.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:4 |
|---|---|
| Enthalten in: |
European heart journal. Case reports - 4(2020), FI1 vom: 07. Okt., Seite 1-6 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chitturi, Kalyan R [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Revised 17.04.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1093/ehjcr/ytaa188 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM316580252 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM316580252 | ||
| 003 | DE-627 | ||
| 005 | 20231225161409.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/ehjcr/ytaa188 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1055.xml |
| 035 | |a (DE-627)NLM316580252 | ||
| 035 | |a (NLM)33089052 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chitturi, Kalyan R |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Successful treatment of acute heart failure in COVID-19-induced cytokine storm with tocilizumab |b a case report |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 17.04.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology. | ||
| 520 | |a BACKGROUND: SARS-CoV-2 is known to induce a cytokine storm, a hyperinflammatory state driven by up-regulation of interleukin 6 (IL-6) and immunomodulatory chemokines that may result in acute heart failure | ||
| 520 | |a CASE SUMMARY: A 65-year-old woman with confirmed SARS-CoV-2 developed shock with multiorgan system failure, including acute biventricular heart failure, 2 weeks after the initial onset of fever, cough, and shortness of breath. The patient experienced myocardial recovery within 48 h after administration of tocilizumab, a humanized monoclonal anti-IL-6 receptor antibody, and multiple supportive vasoactive medications | ||
| 520 | |a DISCUSSION: The differential diagnosis of acute heart failure in critically ill patients with COVID-19 infection is broad, including sepsis-induced cardiomyopathy, Takotsubo syndrome, viral lymphocytic myocarditis, and acute coronary syndrome. Immunomodulatory treatment with tocilizumab may benefit patients who develop cardiogenic shock associated with SARS-CoV-2-induced cytokine storm | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Case report | |
| 650 | 4 | |a Cytokine | |
| 650 | 4 | |a Heart failure | |
| 650 | 4 | |a Myocarditis | |
| 650 | 4 | |a Takotsubo | |
| 650 | 4 | |a Tocilizumab | |
| 700 | 1 | |a Thacker, Sameer |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Saadi, Mukhtar A |e verfasserin |4 aut | |
| 700 | 1 | |a Kassi, Mahwash |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European heart journal. Case reports |d 2017 |g 4(2020), FI1 vom: 07. Okt., Seite 1-6 |w (DE-627)NLM290043824 |x 2514-2119 |7 nnns |
| 773 | 1 | 8 | |g volume:4 |g year:2020 |g number:FI1 |g day:07 |g month:10 |g pages:1-6 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/ehjcr/ytaa188 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 4 |j 2020 |e FI1 |b 07 |c 10 |h 1-6 | ||